ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
70 hedge funds and large institutions have $230M invested in ESSA Pharma in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 9 closing their positions.
7,200% more call options, than puts
Call options by funds: $146K | Put options by funds: $2K
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
17% more funds holding
Funds holding: 60 → 70 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.39% less ownership
Funds ownership: 84.89% → 84.5% (-0.39%)
57% less capital invested
Capital invested by funds: $530M → $230M (-$300M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$13.6M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$7.49M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$7.42M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$6.14M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$12.3M |
| 2 |
Blackstone Inc
New York
|
-$11.4M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$10.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.49M |
| 5 |
FM
Frazier Management
Seattle,
Washington
|
-$7.72M |
EPIX Hedge Fund Activity: Q1 2022 in Review
70 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q1 2022, worth a combined $230M — down 57% from $530M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new EPIX positions and 9 closed out — a net gain of 10 holders — while 22 added to existing stakes and 14 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $13.6M. The largest seller was Logos Global Management, exiting entirely with an estimated $12.3M sold.
- 70 institutional investors held ESSA Pharma (EPIX) as of Q1 2022, up from 60 in Q4 2021.
- Funds reported $230M of ESSA Pharma stock for Q1 2022, down 57% quarter-over-quarter.
- 19 funds opened new ESSA Pharma positions in Q1 2022 and 9 closed out, a net change of +10 holders.
- The largest ESSA Pharma buyer in Q1 2022 was Morgan Stanley, an estimated $13.6M added.
- The largest ESSA Pharma seller in Q1 2022 was Logos Global Management, an estimated $12.3M sold.
Based on aggregated 13F filings for Q1 2022.